The new guidelines provide important updates in four key areas, including behavioral screening for possible HIV transmission, sexually transmitted disease screening and treatment, HIV partner services, and referral for medical and social services.
The ECTRIMS conference may be based in Europe but as the conference has grown so has its global impact on multiple sclerosis treatment. With topics ranging from newly approved therapies to those in the pipeline to those not yet ready for testing there is lots to learn in the yearly event.
In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.
A pair of phase III studies revealed positive efficacy and safety outcomes for ocrelizumab, and this could be a game-changer for patients with multiple sclerosis (MS).
Study results suggest that maintaining proper weight is not just associated with better disease outcomes but also less pain in patients with knee osteoarthritis.
Researchers reported that treatment with isotretinoin is not only associated with significant clinical improvement in patients with moderate to severe acne, but it also did not cause worsening of depression or suicidal thoughts in any of the patients in the study.
Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient’s quality of life (QoL). But by how much?
Results from clinical trials that included patients with relapsing-remitting multiple sclerosis (RRMS) do not appear to be consistent for patients with primary progressive multiple sclerosis (PPMS), according to Markus W. Koch, MD, from the University of Calgary in Alberta, Canada.
It’s not uncommon for patients with multiple sclerosis (MS) to experience a reduction in brain volume. However, treatment with alemtuzumab can slow the process, according to a multi-continental team of investigators.